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Abstract
Celiac disease (CD) is now recognized as a common 
disorder among Middle Eastern (ME) and North African 
(NA) populations. The aim of this review is to assess 
the available data regarding CD in the ME and NA 
and to compare this information with that of Western 
countries. A literature review was performed using the 
electronic databases PubMed and Medline (1950-2008) 
as search engines, and “celiac disease” was used as 
a Mesh term. The search was limited to ME and NA 
countries. The prevalence of CD in ME and NA coun-
tries among low risk populations is similar to that of 
Western countries, but is higher in high risk popula-
tions such as those with type 1 diabetes. It is under-
estimated because of lack of clinical suspicion and lack 
of patient awareness. Clinical presentations in term of 
gastrointestinal, hematologic, skeletal, and liver mani-
festations are similar between both populations except 
for a high prevalence of short stature in some ME and 
NA countries. Few studies have addressed atypical or 
silent CD. As in the West, diagnosis is initially made by 
serological tests and is confirmed by small intestinal 
biopsies. Gluten-free diet is the main mode of treat-
ment with a higher apparent adherence rate than 
in the West. Most disease complications result from 
malabsorption. The disease is strongly associated with 
HLA DQ2 and to a lesser extent with HLA DQ8 alleles. 
In conclusion, CD prevalence is underestimated, with 
little data available about its malignant complications. 
Disease parameters in the ME and NA are otherwise 
similar to those in Western countries.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Celiac disease (CD) is an autoimmune disorder which af-
fects genetically predisposed individuals upon the inges-
tion of  gluten. Its prevalence has been underestimated, 
but it is now considered one of  the most common genetic 
disorders in the West with a prevalence of  1%-2.67%[1-3]. 
In Middle Eastern (ME) and North African (NA) 
countries, the literature regarding CD has expanded signif-
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icantly. The number of  original articles published from the 
region during the last 30 years is about 120 with around 30, 
29, 16, and 10 articles coming from Israel, Turkey, Tunisia, 
and Iran, respectively. Most studies are epidemiological. 
The true prevalence of  the disease is underestimated and 
its clinical features have not been fully determined due to 
small sample size, selection bias, limited knowledge about 
CD and limited funds available for research. 
The aims of  this review of  CD in ME and NA coun-
tries are to compare the disease parameters to those in 
Western countries, namely its epidemiology in low and 
high risk populations, its most common clinical pre-
sentations, the diagnostic tests used and their reported 
sensitivity and specificity. In addition, we determine the 
efficacy of  the treatment modalities used, compliance 
with a gluten-free diet (GFD) and disease complications. 
EPIDEMIOLOGY OF CD IN THE MIDDLE 
EAST AND NORTH AFRICA
Until the 1990s, the prevalence of  CD in ME and NA 
countries was considered low. However, with the intro-
duction of  anti-endomysial antibodies (AEA) and anti-
gliadin antibodies (AGA) testing, CD has been more 
readily reported from developing countries[4], and its 
prevalence seems similar to that of  Western countries[4-7]. 
However, this prevalence varies from 0.14% to 1.17% in 
low risk, and from 2.4% to 44% in high risk populations 
(Tables 1 and 2). This difference is attributed to the het-
erogeneity of  the studied populations, subject selection, 
diagnostic strategies used, and whether confirmatory biop-
sies were performed or not. For example, two studies from 
Tunisia reported a five-fold difference in CD prevalence, 
probably due to the use of  different screening methods[8,9].
CD in low risk populations
Prevalence of  CD among low risk populations ranges 
from 0.14% to 1.3% as assessed by serological markers 
and from 0.033% to 1.17% assessed by biopsies (Table 1). 
The prevalence was found to be > 1% in two studies from 
Turkey[5,6], 0.5%-1% in six reports from Turkey, Egypt, 
Iran, Tunisia and Israel[7,8,10-13], and < 0.5% in five reports 
from Jordan, Lebanon, Tunisia, and Kuwait[9,14-17].
Most studies screened healthy blood donors[6,9-11,17], 
of  whom young males represented > 70%. One study 
screening healthy individuals for CD in Iran, 50% of  
whom were females, reported a similar disease prevalence 
of  1% among both men and women[7]. On the other 
hand, Green et al[2] reported that the disease was 2 to 3 
times more common in women. Another study from 
Tunisia on healthy blood donors, 30% of  whom were 
females, reported a disease prevalence of  0.4% among 
women compared to 0.22% among men[17]. Exclusion 
of  subjects with iron deficiency anemia (IDA), abnormal 
liver function tests (LFTs) and the low percentage of  
participating females may have led to the underestimation 
of  disease prevalence. In addition, low suspicion among 
physicians may have contributed to the low reported inci-
dence of  CD[8,14]. Finally, studies restricted to patients pre-
senting with severe symptoms might have underestimated 
the true prevalence of  the disease by missing asymptom-
atic and mildly symptomatic individuals[15]. 
CD in high risk populations
High risk populations include patients with positive fam-
ily history, insulin dependent diabetes mellitus (IDDM) 
and/or thyroiditis, and those with symptoms of  malab-
sorption such as chronic diarrhea, refractory IDA and 
weight loss. Among these, the prevalence of  CD ranges 
from 2.4% to 44% assessed by serological markers and 
biopsies (Table 2). 
In Western countries, the prevalence of  CD among 
patients with IDDM is 1%-12% assessed by serological 
markers and 1%-11% by biopsies[1]. The disease is more 
common in children than adults with IDDM. In nine 
reports from ME and NA countries, the prevalence of  
CD among IDDM patients was 2.4%-20% assessed by 
serological markers and 2.4%-16.4% by biopsies (Table 2). 
Small sample size and a high rate of  consanguinity may 
have contributed to the high prevalence. CD and IDDM 
share many genetic factors including HLA DR3-DQ2 and 
HLA DR4-DQ8 haplotype[18,33]. 
CD is common in patients with autoimmune thyroid 
diseases. In Western countries a prevalence of  4%-5% is 
reported[34,35], with an average of  1.5%-6.7% as assessed 
by serological markers and 3% by intestinal biopsies[1]. The 
prevalence of  CD among Tunisian patients with Grave’s 
disease was 3.7% by serological markers and 2.5% by bi-
opsies[19]. An increased prevalence of  autoimmune thyroid 
antibodies among CD patients on a GFD[36] has also been 
reported. In Turkey, 5.9% of  patients with autoimmune 
thyroiditis had positive CD serology[20]. Autoimmune thy-
roid disease and CD share a common genetic background 
(HLA DQ2 and HLA DQ8)[20].
Prevalence of CD in relatives
In the US, the prevalence of  CD was found to be 4.5% 
and 2.5% in first and second-degree relatives of  patients 
with the disease, respectively[3]. The National Institutes 
of  Health (NIH) estimates the prevalence of  CD among 
first degree relatives to be 4%-12%, assessed by biopsy.
In two studies from Algeria and Turkey, the preva-
lence of  CD in patients’ first degree relatives was 3.4% 
and 1.7%, respectively[21,33]. Among 381 first degree rela-
tives, 26 had positive serology, and villous atrophy was 
present in 13 of  16 who had biopsies performed[21]. Also, 
clustering of  CD within families has been reported from 
Jordan and Algeria[14,21]. There are no twin studies of  CD 
in ME and NA countries. The high rate of  consanguin-
ity in these countries might contribute to a higher preva-
lence of  CD and provides an opportunity for studying 
genotype-phenotype correlations.
CLINICAL PRESENTATION
The clinical presentation of  CD varies from silent dis-
ease to full-fledged severe intestinal and extra-intestinal 
manifestations[1,2,37]. A study comparing Turkish and US 
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patients found that the former presented mostly with di-
arrhea and anemia and the latter with atypical symptoms 
such as fatigue, abdominal pain and bloating[38]. Whereas 
some reports from Turkey, Jordan and Iran address 
silent and atypical CD[5,14,39], little is known about the 
prevalence and the clinical, serologic and histopathologic 
features of  patients with atypical or silent CD in this re-
gion, the so-called celiac iceberg. 
GI manifestations
GI complaints are the most common presenting symp-
toms. They include diarrhea, abdominal pain, constipa-
tion, bloating, flatulence, nausea and vomiting. Lo et al[40] 
report a drop in the percentage of  CD patients present-
ing initially with diarrhea to 43%, compared to 73% be-
fore 1993. 
Among six studies assessing chronic diarrhea in ME 
and NA countries, CD prevalence was 6.5%-21%[22,23,41-44]. 
In Iran, Lebanon, Iraq, Saudi Arabia and Kuwait, CD 
was one of  the most common causes of  chronic diar-
rhea[22,41-44]. In Egypt, 4.7% of  children presenting with 
diarrhea and failure to thrive had CD[13].
The reported prevalence of  GI manifestations has 
varied widely among different studies (Table 3). This 
may be due to the low number of  patients evaluated or 
a delay in their presentation. For example, al-Hassany[45] 
reported 10 cases with advanced CD who all had diar-
rhea, abdominal distension and weight loss. Diarrhea 
and abdominal distension were significantly more com-
mon in younger children, whereas abdominal pain, fail-
ure to thrive and growth retardation were more common 
among those who were older. This is attributed to the 
predominance of  classical CD among younger children 
versus atypical CD seen among older children[14,46].
About one third of  children with CD in Western coun-
tries develop short stature[50]. In ME and NA countries, 
short stature was discovered to be the presenting symptom 
in 7.7% to 53% of  patients. The highest prevalence of  
short stature was reported from Jordan where 26% of  chil-
dren with CD had rickets. In Turkey, 51% of  patients had a 
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Table 1  Prevalence and incidence of celiac disease in Middle Eastern and North African countries among low risk populations
Country Population Method Confirmation by 
duodenal biopsy
Result
Central Anatolia, Turkey[5] 906  hospitalized adults t-TG1 Yes Prevalence 1%
Turkey[6] 2000 healthy blood donors t-TG1,2 Yes (incomplete) Prevalence by serology 1.3% and by histology 1.17%
Iran[7] 2799 healthy individuals t-TG1, AEA1 Yes Prevalence 0.96%
Tunisia[8] 6286 school children t-TG1, AEA1 Yes (incomplete) Prevalence 0.64%
Tunisia[9] 1418 healthy blood donors AEA1 Yes Prevalence 0.14%
Iran[10] 2000 healthy blood donors AGA1, AEA1 Yes Prevalence 0.6%
Israel[11] 1571 healthy blood donors AEA1, t-TG Yes (incomplete) Prevalence 0.63%
Turkey[12] 1263 healthy school children t-TG1 Yes (incomplete) Prevalence by serology 0.87% and by histology 0.63%
Egypt[13] 1500 healthy children t-TG1,2, AEA1 Yes Prevalence 0.53%
Jordan[14] 494 000 children No serology done Yes Incidence 1 in 2800 live births, point prevalence 7:100 000
Kuwait[15] 60 000 newborn over 5 years NR Yes 1 in 3000 births
Lebanon[16] 42 600 hospitalized children AGA, AEA Yes 5 per 1000 hospital admissions
Tunisia[17] 2500 healthy blood donors AGA1,2, AEA1 No Prevalence 0.3%
1IgA; 2IgG. AEA: Anti-endomysial antibodies; AGA: Anti-gliadin antibodies; tTG: Tissue transglutaminase; NR: Not reported.
Table 2  Prevalence of celiac disease in Middle Eastern and North African countries among high risk populations
Country Population Method Confirmation by duodenal biopsy Prevalence (%)
Egypt[13] 150 children with diarrhea and failure to thrive t-TG1,2, AEA1 Yes 4.7
250 children with IDDM t-TG1,2, AEA1 No 6.4
Saudi Arabia[18] 123 pts with IDDM AGA1, ARA1 Yes (incomplete)       4.9-8.1
Tunisia[19] 161 pts with Grave disease AEA1, t-TG1 Yes (incomplete) 3.7
Turkey[20] 136 pts with autoimmune thyroiditis t-TG1 Yes (incomplete) 5.9
Algeria[21] 116 children with IDDM AGA1,2, AEA1 Yes     16.4-20
Iran[22] 100 pts with chronic diarrhea AGA1, AEA1 Yes           19
Iran[23] 825 children with chronic diarrhea AGA1, AEA1 Yes 6.5
Iran[24] 250 pts with IDDM Total IgA, AEA1 Yes 2.4
North-Eastern Libya[25] 243 pts with high clinical suspicion NR Yes           31.7
Eastern Saudi Arabia[26] 145 pts with high clinical suspicion AEA1, ARA1 Yes   4-11
Egypt[27] 25 pts with refractory iron deficiency anemia AGA2, AEA1, t-TG2, ARA Yes           44
Turkey[28] 100 pts with IDDM AEA1 Yes             6
Iraq[29] 40 pts with IDDM NR Yes           15
Libya[30] 234 pts with IDDM AGA, t-TG, ARA, AEA Yes           10.3
Tunisia[31] 348 pts with IDDM AEA1, t-TG Yes    2.6-4
Turkey[32] 122 pts with IDDM Total IgA, AEA1 Yes   2.45
1IgA; 2IgG. IDDM: Insulin dependent diabetes mellitus.
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height < 2.5 standard deviations below the mean[47]. 
Many CD patients are initially diagnosed as having 
irritable bowel syndrome (IBS). Green et al[51] reported 
that up to 36% of  American patients with CD were pre-
viously diagnosed with IBS. In Iran, 12% of  IBS labeled 
patients turned out to have CD[39].
Hematological manifestations
The prevalence of  anemia at the time of  CD diagnosis 
is 12%-69%[52]. IDA is the most common form and may 
be the only finding in 45% of  patients with sub-clinical 
CD[53]. Worldwide prevalence of  CD among patients 
with IDA is 2.8%-8.7% and may be as high as 15%[54,55]. 
Folate and B12 deficiency may contribute to anemia 
in CD, and surprisingly, anemia of  chronic disease is 
relatively common[52]. In ME and NA countries, anemia 
occurs in 20%-80% of  CD patients and the majority of  
cases are attributable to iron deficiency[14,15,22,24-26,33,45-47]. 
An Egyptian study found that 4% of  young IDDM 
patients with anemia had CD[56]. Another paper reports 
a CD prevalence of  44% among 25 Egyptian patients 
evaluated for refractory IDA[27].
Osteoporosis
The prevalence of  osteopenia and osteoporosis in CD 
patients is 30%-50% and 3.4%-14%, respectively[57,58]. In 
ME and NA countries, 5 studies of  CD patients report-
ed a prevalence of  hypocalcemia of  3.3%-27.4%[33,45,46] 
and of  osteoporosis of  13.5%-16.7%[33,39]. In Saudi Ara-
bia, osteomalacia and IDA were the most common pre-
senting symptoms, accounting for 43.5% of  the clinical 
presentations[48]. In Tunisian children with CD diagnosed 
by screening, osteopenia prevalence was 34.7%[8]. Delay 
in the diagnosis of  CD may account for the high preva-
lence of  osteoporosis[33]. 
Abnormal LFTs
Hypertransaminasemia is an early manifestation of  liver 
involvement in CD. Five to 10% of  patients with elevated 
serum aminotransferases end up being diagnosed with 
CD[59]. Liver biopsy may reveal lesions ranging from reac-
tive hepatitis to cirrhosis, which may be partially or totally 
reversed with a GFD. In ME and NA countries, few stud-
ies have reported abnormal LFTs among patients with 
CD[21,46]. A Turkish study reported increased transaminases 
and hypoproteinemia in 38.3% and 4% of  CD patients, re-
spectively[46]. The latter may be attributed to protein-losing 
enteropathy and/or decreased hepatic synthetic activity[46]. 
An Iranian group reported increased transaminases among 
25% of  CD patients[22]. Transaminases levels normalized in 
all patients, except those with cirrhosis, on a GFD[22,46].
Prevalence of autoimmune diseases among patients 
with CD
About 30% of  patients with CD have other autoimmune 
disorders such as IDDM and autoimmune thyroiditis[60,61]. 
In ME and NA countries, the prevalence of  autoim-
mune diseases among CD patients was demonstrated to 
be as low as 1.9% in Turkish patients[46] and as high as 
33% in Iranian patients[28]. Many of  these patients were 
diagnosed with CD after substantial delays[39]. The preva-
lence of  IDDM in CD patients is 6.7%-18.5% and af-
fected patients are typically older than those with IDDM 
alone[33,39,48]. They are mostly females with longer duration 
of  diabetes[24]. Autoimmune diseases are more common 
in patients with IDDM and CD than in those with CD 
or IDDM alone[28,33,62]. In a Turkish study, adult patients 
with IDDM and CD had a 33.33% prevalence of  other 
autoimmune diseases such as autoimmune thyroiditis[28]. 
This may be an overestimation due to small sample size. 
Importantly, a French study demonstrated a reduction in 
the development of  autoimmune diseases among CD pa-
tients adherent to a GFD compared to those not adherent 
to such a diet[63]. This highlights a major role of  early diag-
nosis and therapy of  CD in order to reduce the burden of  
autoimmunity. 
DIAGNOSIS
The diagnosis of  CD is challenging and requires a high 
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Table 3  Clinical presentation of celiac disease in the Middle East and North Africa










Iran[7] 29 adults with CD detected by screening 55.5 22.2 NR NR 18.5
Jordan[14] 34  pts with CD 44.0 65.0 53.0 NR 44.0
Kuwait[15] 20 children with CD 80.0      100.0 25.0 (rickets) 100.0 NR
Lebanon[16] 65 children with CD 26.2 60.0 NR   49.2 NR
Turkey[33] 60 Adults with CD 48.3 66.7 NR   50.0 NR
Iran[39] 52 pts with CD 32.7 48.1 23.1   78.8 NR
Iraq[45] 10 children with CD                 100.0      100.0 NR 100.0 NR
Turkey[46] 104 children with CD 60.6 81.7 45.2 44.0-50.0 23.0
Turkey[47] 45 children with CD NR 40.0 51.0 NR NR
Libya[25] 77 children with suspected CD 49.0 53.0 23.0 100.0 15.0
Saudi Arabia[26] 10 children with suspected CD NR 50.0 10.0   30.0 30.0
Egypt[27] 11 pts with anemia and CD 18.2 45.5 45.5   57.1 63.6
Saudi Arabia[48] 16 adults with CD NR 37.0 18.5 NR 18.5
Libya[49] 39 pts with with CD 61.5 59.0   7.7   82.0 20.5
CD: Celiac disease.
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level of  suspicion. All screening algorithms start with se-
rological tests and include testing for IgA and IgG anti-
gliadin antibodies (AGA), IgA and IgG anti-endomysial 
antibodies (AEA), IgA and IgG tissue transglutaminase 
(tTG) and a new generation of  anti-gliadin antibodies 
to deamidated synthetic gliadin peptides (DGP)[64]. The 
AEA test is currently the gold standard because of  its 
high sensitivity and almost 100% specificity[1,65]. Fur-
thermore, high levels of  both AEA and tTG have very 
high sensitivity and specificity[66]. Small intestinal biopsy 
remains the gold standard diagnostic test[1,67]. 
Diagnosis of CD in ME and developing countries
In 24 out of  28 studies of  prevalence of  CD in ME and 
NA countries, patients were initially screened with sero-
logical tests. In those testing positive, confirmation of  
the diagnosis by duodenal biopsy was performed in the 
majority of  cases. In 7 out of  24 studies, confirmation 
by biopsy was incomplete (Tables 1 and 2). In 4 stud-
ies, intestinal biopsies were the initial mode of  diagnosis 
because of  the unavailability of  serological tests[14,15,25,29]. 
Serological marker sensitivity and specificity varied 
widely because of  difference in the choice of  gold stan-
dard, bias in patient selection, population differences 
and methodology used, including number of  biopsies 
(Table 4). AEA sensitivity ranges from 20%[7,11] to > 
90%[17,46,68], with a specificity reaching 100%[7,11,26,68]. The 
low AEA sensitivity reported from 2 studies conducted 
in Iran and Israel is attributed to improper intestinal 
mucosal sampling, the low power of  AEA-immunoflu-
orescence in detecting early CD, and the poor perfor-
mance of  the AEA in the presence of  milder degrees 
of  villous atrophy[11,69]. These factors may have resulted 
in missing many cases of  CD[7,11]. tTG IgA sensitivity is 
70%-100%[6,7,57], and specificity is 99%[7]. The sensitivity 
of  IgA AGA is about 80%, while that of  IgG AGA is 
90%-100%[17,27,46]. AEA testing was used in 19 out of  24 
studies, while t-TGA and AGA testing were used in 12 
and 9 studies, respectively (Tables 1 and 2). While the 
serological tests have shown high sensitivity and specific-
ity for the diagnosis of  CD, there are problems including 
differences in test kit sensitivity and specificity[70], as well 
as an apparent lower performance in the clinical setting 
compared to research laboratories[71]. 
The Marsh classification is a histologic grading sys-
tem that reflects the varying degrees of  intestinal muco-
sal villous atrophy and inflammatory changes that occur 
in patients with CD[1]. March classification is used by 
almost all investigators in the histological diagnosis and 
classification of  CD severity.
TREATMENT
A GFD remains the mainstay of  CD treatment. Ad-
herence to a GFD in Western countries is reported to 
be less than 50%[72]. Treatment with a GFD results in 
improvement of  many clinical and serological param-
eters[1,73]. Also, adherence to a GFD for five consecutive 
years or more significantly reduces the incidence of  ma-
lignancies such as cancer of  the mouth, pharynx, esoph-
agus and lymphoma[74]. Moreover, adherence to a GFD 
has a protective effect on the development of  many au-
toimmune diseases such as IDDM, inflammatory bowel 
diseases, hepatitis and hematologic disorders[63].
Adherence to a GFD in ME and NA countries rang-
es from 50% to 100%[10,14,15,18,22,23,39,59,62]. The vast majority 
of  adherent patients have good response ranging from 
60% to 100%[10,14-16,18,22,23,28,39,48,49]. Moreover, patients’ 
level of  compliance and response were used interchange-
ably in some studies[14,15,48]. The higher level of  adherence 
to a GFD in comparison to Western countries may be 
due to the limited number of  patients studied and the 
use of  less rigorous parameters to assess adherence. 
The reasons for poor compliance are not clear. 
Wheat and barley are major diet constituents with few 
acceptable alternatives[22], rendering the convincing of  
parents that bread is the cause of  diarrhea very hard[15]. 
Also, convincing patients with atypical CD to adhere to a 
GFD is difficult[4]. Finally, lack of  information about CD 
manifestations, lack of  benefit from a GFD and lack of  
encouragement to adhere to such a diet may contribute. 
More than 10% of  adults with CD do not adhere strictly 
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Table 4  Serological diagnosis of celiac disease in Middle Eastern and North African countries
Country Population AGA (%) AEA (%) t-TG Ab (%)
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Turkey[6] 2000 healthy individuals NR NR NR NR 90.0 NR
Iran[7] 2799 healthy individuals NR NR 19.0         100.0         100.0 99.0
Israel[11] 1571 healthy blood donors NR NR 20.0         100.0 50.0-60.0 25.0-38.0
Tunisia[17] 2500 healthy blood donors 100.0 84.0 NR NR NR NR
Algeria[39]1 116 children with IDDM IgA AGA, IgG AGA, and IgA AEA
Sensitivity Specificity
80.0 100.0
Turkey[46] 104 children with CD 76.0 (IgA), 94.0 (IgG) NR 90.0 NR NR NR
Saudi Arabia[26] 145 high risk patients NR NR NR         100.0 NR NR
Egypt[27] 11 children with CD 100.0 21.4 81.8 21.4 72.7 85.7
Israel[68] 39 children with CD and 22 
healthy children
NR NR         100.0         100.0 NR NR
1Sensitivity and specificity of all tests simultaneously.
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to long term GFD and more than 30% who believe 
they are, are actually consuming grams of  gluten daily[4]. 
Diabetic patients adhering to a GFD will have fewer 
episodes of  hypoglycemia and better diabetes control[26]. 
Demir et al[46] report improvement in growth velocity and 
rapid catch up of  height and weight in children with CD 
who adhere to a GFD. Moreover, adherence to a GFD 
resulted in improvement of  hepatic histopathological 
changes. In addition to a GFD, supplementation of  cal-
cium, vitamin D and iron may accelerate normalization 
of  serological markers and reduce the rate of  fractures 
and complications resulting from anemia[39]. 
There are no reports regarding refractory CD or its 
treatment from ME or NA countries. In addition, no tri-
als of  immunosuppressive or immune-modulator drugs 
have been described. Currently, both a permeability 
blocker and oral enzyme preparations are in clinical trials 
in the US and Europe[75-77]. While the safety and effec-
tiveness of  these potential therapies need to be deter-
mined, the financial burden of  the addition of  drugs to 
a GFD may be prohibitive in developing countries.
COMPLICATIONS
Complications of  CD range from malabsorption to 
cerebellar ataxia, dilated cardiomyopathy[78], infertility, 
lymphoma, as well as oropharyngeal, gastrointestinal and 
thyroid malignancies[45,79]. Metabolic bone disease, ma-
lignancies and autoimmune conditions may develop if  
treatment is delayed[80]. 
In the ME and developing countries, most complica-
tions result from malabsorption. Mortality in hospitalized 
patients with CD is relatively increased in the first 3 years 
after diagnosis, particularly in patients with malabsorp-
tion, those with delayed diagnosis, and those poorly 
adherent to a GFD[33]. Prolonged INR due to Vit K 
malabsorption is found in 25% of  patients and improves 
on a GFD[81]. However, low levels of  serum cholesterol, 
HDL, LDL and phospholipids in 46 Algerian patients 
with CD did not improve on a GFD[82]. Hypocalcemia 
and hypovitaminosis D contribute to osteoporosis which 
occurs in 16.7%[43] of  CD patients, similar to what is 
reported in Western countries[57,83]. There have been case 
reports of  hepatic vein thrombosis in North African 
subjects with CD[84,85]. 
A mortality rate of  3.3% was reported in 60 Turk-
ish patients with CD, mainly due to malignancies[33]. 
In Turkey and Iran, non-Hodgkin lymphomas are the 
most common CD-associated malignancies[33,39]. Similar 
to Western countries, there is an increased prevalence 
of  gastrointestinal malignancies and of  non-Hodgkin 
lymphoma in CD patients. Oropharyngeal malignancies, 
as well as neurological, cardiac and cutaneous compli-
cations of  CD, have been described in Western coun-
tries[1,2,37,78,79], but have not been well documented in ME 
countries. Left ventricular subclinical systolic dysfunc-
tion has been reported in Turkish children with CD, with 
a negative correlation between myocardial systolic wave 
and serum IgA AEA level[86].
Mortality rate among hospitalized patients with CD 
in Turkey was found to be increased 2-fold[33], although 
it is not clear what the control group was in this study. 
While increased mortality in CD patients has been well 
documented in the West using standardized mortality ra-
tio (SMR)[1], which is the ratio of  observed deaths in pa-
tients with celiac disease to expected deaths on the basis 
of  age- and sex-specific rates in the region under study, 
no such data has been published from the Middle East. 
GENETICS
Most CD patients have HLA DQ2 or HLA DQ8 alleles, 
which account for 40% of  the total genetic predisposi-
tion to CD[1,2]. Moreover, HLA DQ2 and DQ8 are ex-
pressed in 30% of  the general population, suggesting the 
presence of  additional factors for CD development. One 
such factor is CTLA-4 gene polymorphism, a non HLA 
gene thought to regulate T-cell immune function[87]. As 
in the West, CD is found in ME and NA countries to 
be strongly associated with HLA DQ2 (DQA1*0501 
and DQB1*0201)[88-93]. HLA DQ8 (DQA1*0301 and 
DQB1*0302) is less strongly associated with CD[92]. 
HLA B8, a gene expressed in MHC Ⅰ antigen present-
ing cells, is found to be associated with CD in Algeria[89], 
Iraq[94,95] and Turkey[91]. Carriers of  this gene are at in-
creased risk of  developing CD[91]. In addition, Saharawi 
patients with atypical CD were found to over-express 
the MHC class Ⅰ chain-related gene A (MICA) allele 
5.1[89]. These associations have been reported in Western 
countries[96]. Increased prevalence of  HLA-A25(10) in 
Turkish children with CD is reported, suggesting that 
this genotype is particularly encountered among this 
population[91]. No such association has been described in 
Western countries.
CONCLUSION
The prevalence of  CD disease in ME and NA countries 
may be underestimated due to lack of  awareness and low 
suspicion of  the disease. Whether mass screening for 
the disease should be done in high risk populations, such 
as patients with short stature, chronic diarrhea, IDA, 
IDDM, and those with a positive family history is not 
clear. The best screening modality is not yet determined, 
though tTG IgA is probably the most economic.
Large prospective studies are needed to assess the 
true incidence, the clinical course, the efficacy of  treat-
ment modalities employed, patient compliance, disease 
complications and response to treatment in ME and 
NA countries. The association of  CD with other auto-
immune diseases and the presence of  specific genetic 
markers would be areas of  interesting future research. 
The high rate of  consanguinity among people of  the 
same ethnic background in this part of  the world might 
provide an opportunity for establishing genotype-pheno-
type correlations in CD.
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